ÀǾàǰ Á¦3ÀÚ ¹°·ù ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ¿Âµµº°, Ä¡·á ºÐ¾ßº°, Á¦Á¶¾÷ü ±Ô¸ðº°, ¼­ºñ½ºº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Pharmaceutical Third-Party Logistics Market Size, Share & Trends Analysis Report By Product, By Temperature, By Therapeutic Area, By Manufacturer Size, By Service, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1654146
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,320,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,718,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,515,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀǾàǰ Á¦3ÀÚ ¹°·ù ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ÀǾàǰ Á¦3ÀÚ ¹°·ù ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 8.95%·Î È®´ëµÇ¾î 2030³â¿¡´Â 2,285¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀ» °ßÀÎÇÏ´Â °ÍÀº ¾ö°ÝÇÑ ±ÔÁ¦ »óȲ, »ý¹° Á¦Á¦ ¹× À¯ÀüÀÚ Ä¡·á¿Í °°Àº »õ·Î¿î Ä¡·á¹ýÀÇ ÃâÇöÀ¸·Î ÀÎÇÑ ÀǾàǰ À¯Åë°ú °ü·ÃµÈ °úÁ¦ Áõ°¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ º¹À⼺Àº ¸¹Àº Á¦¾à ȸ»çµéÀÌ »ç³»¿¡¼­ ºÎÁ·ÇÑ ¹°·ù Àü¹® Áö½ÄÀ» ÇÊ¿ä·Î ÇÏ°í ¿¬±¸ °³¹ß°ú °°Àº ÇÙ½É ¿ª·®¿¡ ÁýÁßÇϱâ À§ÇØ ¹°·ù ±â´ÉÀ» 3PL °ø±ÞÀÚ¿¡°Ô ¾Æ¿ô¼Ò½ÌÇϵµ·Ï Ã˱¸ÇÕ´Ï´Ù.

°Ô´Ù°¡, ¿Âµµ°ü¸®µÈ ¹°·ù¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎ Áß Çϳª°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀϺΠÀǾàǰ, ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹é½ÅÀº Á¦Á¶¿¡¼­ ¹è¼Û±îÁö °ø±Þ¸Á Àü¹Ý¿¡ °ÉÃÄ ¿Âµµ °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¿Âµµ¿¡ ¹Î°¨ÇÑ Á¦Ç°ÀÇ ¹«°á¼º°ú È¿À²¼ºÀ» º¸ÀåÇÏ·Á¸é Àü¹®ÀûÀÎ ÄݵåüÀÎ ±â´ÉÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº À¯Åë °øÁ¤ Àü¹Ý¿¡ °ÉÃÄ ÇÊ¿äÇÑ ¿Âµµ Á¶°ÇÀ» À¯ÁöÇϱâ À§ÇÑ Àü¹® Áö½Ä°ú ÀÎÇÁ¶ó¸¦ °®Ãá 3PL °ø±ÞÀÚ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ³ô¿© ÁÝ´Ï´Ù.

°Ô´Ù°¡ ±â¼úÀÇ Áøº¸´Â ÀǾàǰ ¹°·ùÀÇ Àü¸ÁÀ» Å©°Ô ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ºí·ÏüÀÎ, »ç¹°ÀÎÅͳÝ(IoT), ÀΰøÁö´É(AI)°ú °°Àº ÷´Ü ±â¼úÀÇ ÅëÇÕÀº °ø±Þ¸ÁÀÇ °¡½Ã¼º¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ Àç°í °ü¸®¸¦ °­È­Çϰí ÃâÇÏÀÇ ½Ç½Ã°£ ÃßÀû ¹× ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ 3PL Á¦°ø¾÷ü´Â ¹°·ù ¾÷¹«¸¦ ÃÖÀûÈ­Çϰí À§ÇèÀ» ÃÖ¼ÒÈ­Çϸç Àû½Ã¿¡ È¿À²ÀûÀ¸·Î ÀǾàǰÀ» ȯÀÚ¿¡°Ô Àü´ÞÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

ÀǾàǰ 3PL ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº °æÀï·ÂÀ» À¯ÁöÇϰí ÀǾàǰ ¾÷°èÀÇ ÁøÈ­ÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ¼¼°èÀûÀÎ Á¸Àç È®´ë, ÄݵåüÀÎ ´É·Â °­È­, ÷´Ü ±â¼ú ÅëÇÕ¿¡ Àü·«ÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¼¼°è ÀǾàǰ °ø±Þ¸ÁÀÇ º¹À⼺°ú ¿Âµµ º¯È­¿¡ ¹Î°¨ÇÑ Á¦Ç°ÀÇ ¼ö¼Û Áõ°¡·Î 3PL °ø±Þ¾÷ü´Â ÄݵåüÀÎ ¹°·ù ÀÎÇÁ¶ó¸¦ °­È­Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅõÀÚ´Â ¿Âµµ °ü¸® â°í ¹× ³ÃÀå ¼ö¼Û°ú °°Àº ¼¶¼¼ÇÑ ÀǾàǰÀ» ¾ÈÀüÇϰí È¿°úÀûÀ¸·Î Àü´ÞÇÒ ¼ö ÀÖ´Â ÃֽŠ½Ã¼³À» ¼ö¸³ÇÏ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù. ¿¹¸¦ µé¾î DHL °ø±Þ¸ÁÀº 2024³â 2¿ù »ý¸í°úÇаú °Ç°­ °ü¸®ÀÇ ¹°·ù ¾÷¹«¸¦ È®´ëÇϱâ À§ÇØ 2¾ï ´Þ·¯¸¦ ÅõÀÚÇÒ °ÍÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÅõÀÚ´Â ¿Âµµ¿¡ ¹Î°¨ÇÑ ÀǾàǰ Ãë±Þ¿¡¼­ DHLÀÇ ´É·ÂÀ» Çâ»ó½ÃÄÑ ÄݵåüÀÎ ¹°·ù¿Í ÄÄÇöóÀ̾𽺸¦ Çâ»ó½Ãŵ´Ï´Ù.

ÀǾàǰ Á¦3ÀÚ ¹°·ù ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ÀǾàǰ Á¦3ÀÚ ¹°·ù(3PL) ¼­ºñ½º ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ÀǾàǰ Á¦3ÀÚ ¹°·ù(3PL) ¼­ºñ½º ½ÃÀå : ¿Âµµ º¯µ¿¡¤µ¿Ç⠺м®

Á¦6Àå ÀǾàǰ Á¦3ÀÚ ¹°·ù(3PL) ¼­ºñ½º ½ÃÀå : Ä¡·á ºÐ¾ßÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ÀǾàǰ Á¦3ÀÚ ¹°·ù(3PL) ¼­ºñ½º ½ÃÀå : Á¦Á¶¾÷ü ±Ô¸ðÀÇ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå ÀǾàǰ Á¦3ÀÚ ¹°·ù(3PL) ¼­ºñ½º ½ÃÀå : ¼­ºñ½º ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦10Àå °æÀï ±¸µµ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pharmaceutical Third-Party Logistics Market Growth & Trends:

The global pharmaceutical third-party logistics market is expected to reach USD 228.54 billion by 2030, expanding at a CAGR of 8.95% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven due to stringent regulatory landscapes, and the emergence of novel therapies like biologics and gene therapies which have increased the challenges associated with drug distribution. This complexity requires specialized logistics expertise that many pharmaceutical companies lack internally, encouraging them to outsource logistics functions to 3PL providers to concentrate on their core competencies, such as research and development.

Furthermore, growing demand for temperature-controlled logistics is also one of the factors driving market growth. Several pharmaceutical products, particularly biologics and vaccines, demand temperature control throughout the entire supply chain, from manufacturing to the point of delivery. Thus, to ensure the integrity and efficacy of these temperature-sensitive products necessitates specialized cold chain capabilities. These factors are further driving the demand for 3PL providers with the expertise and infrastructure to maintain the required temperature conditions throughout the entire distribution process.

In addition, technological advancements are also transforming the pharmaceutical logistics landscape. The integration of cutting-edge technologies such as blockchain, the Internet of Things (IoT), and artificial intelligence (AI) is revolutionizing supply chain visibility, enhancing inventory management, and enabling real-time tracking and monitoring of shipments. These technological innovations empower 3PL providers to optimize logistics operations, minimize risks, and ensure timely and efficient delivery of pharmaceuticals to patients.

Key players in the pharmaceutical 3PL market are strategically investing in expanding their global presence, enhancing their cold chain capabilities, and integrating advanced technologies to maintain a competitive edge and meet the evolving demands of the pharmaceutical industry. The increasing complexity of global pharmaceutical supply chains and the rise in the transportation of temperature-sensitive products, have prompted 3PL providers to strengthen their cold chain logistics infrastructure. These investments focus on establishing state-of-the-art facilities, such as temperature-controlled warehouses and refrigerated transport, to ensure the safe and effective delivery of sensitive drugs. For instance, in February 2024, DHL supply chain announced to invest USD 200 million which aims to expand life sciences and healthcare logistics operations. This investment will enhance DHL's capabilities in handling temperature-sensitive pharmaceutical products, improving cold chain logistics and compliance.

Pharmaceutical Third-Party Logistics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Pharmaceutical Third-Party Logistics (3PL) Services Market: Product Estimates & Trend Analysis

Chapter 5. Pharmaceutical Third-Party Logistics (3PL) Services Market: Temperature Estimates & Trend Analysis

Chapter 6. Pharmaceutical Third-Party Logistics (3PL) Services Market: Therapeutic Area Estimates & Trend Analysis

Chapter 7. Pharmaceutical Third-Party Logistics (3PL) Services Market: Manufacturer Size Estimates & Trend Analysis

Chapter 8. Pharmaceutical Third-Party Logistics (3PL) Services Market: Service Estimates & Trend Analysis

Chapter 9. Regional Business Analysis

Chapter 10. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â